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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Bimuno
® GOS and reducing gastro-intestinal discomfort pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following  an  application  from  Clasado  Limited,  submitted  for  authorisation  of  a  health  claim  pursuant  to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Malta, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to Bimuno
® GOS and reducing gastro-intestinal discomfort. The food constituent that is 
the  subject  of  the  health  claim,  Bimuno
®  GOS,  which  is  a  mixture  of  β-galacto-oligosaccharides  produced 
through  conversion  of  lactose  by  enzymes  from  Bifidobacterium  bifidum  NCIMB  41171,  is  sufficiently 
characterised. The claimed effect is reducing gastro-intestinal discomfort and is considered to be a beneficial 
physiological effect. The applicant did not provide any studies from which data could be used for the scientific 
substantiation of the claimed effect of reducing gastro-intestinal discomfort. A cause and effect relationship has 
not been established between the consumption of Bimuno
® GOS and reducing gastro-intestinal discomfort. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following  an  application  from  Clasado  Limited,  submitted  for  authorisation  of  a  health  claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Malta, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 
the scientific substantiation of a health claim related to Bimuno
® GOS and reducing gastro-intestinal 
discomfort. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is Bimuno
® GOS, a mixture of β-galacto-
oligosaccharides, which is produced through conversion of lactose by enzymes from Bifidobacterium 
bifidum NCIMB 41171. The Panel considers that Bimuno
® GOS is sufficiently characterised.  
The claimed effect proposed by the applicant is “reduce bloating, flatulence and abdominal pain: 
these effects can be described collectively as abdominal discomfort”. The target population proposed 
by the applicant is the general adult population. Symptoms such as abdominal pain, cramp, bloating, 
straining,  borborygmi  (rumbling)  and  sensation  of  incomplete  evacuation  are  associated  with 
gastro-intestinal  discomfort.  Reducing  gastro-intestinal  discomfort  is  considered  an  indicator  of 
improved gastro-intestinal function. Gastro-intestinal discomfort may be measured by using validated 
subjective  global  symptom  severity  questionnaires  such  as  described  in  consensus  opinions.  The 
Panel considers that reducing gastro-intestinal discomfort is a beneficial physiological effect.  
Following a literature search in PubMed, the applicant identified four human intervention studies and 
one  review  publication  as  being  pertinent  to  the  health  claim.  The  applicant  also  provided  two 
unpublished human intervention studies and three non-human studies for the scientific substantiation 
of the claim.  
All the human and non-human studies provided by the applicant for this claim were already submitted 
in previous applications for the same claim, and which were assessed by the Panel with unfavourable 
outcomes, except for one unpublished human intervention study. 
This multicentre, placebo-controlled, randomised, double-blind, parallel study investigated the effect 
of  Bimuno
®  GOS  on  symptoms  related  to  gastro-intestinal  discomfort  in  subjects  suffering  from 
gastro-intestinal discomfort (bloating, flatulence, abdominal pain and/or need to defecate) in the past 
12 months. Subjects who had a weekly average composite score of > 10 to questions on flatulence, 
“bowel moments” (difficulty, urgency, straining, sense of incomplete evacuation), abdominal pain and 
abdominal bloating in the week prior to randomisation were randomised to consume Bimuno
® GOS 
(1.37 g/day; n = 208) or maltodextrin (n = 200) daily for four weeks. Participants completed on-line 
questionnaires on “bowel movements”, abdominal pain, bloating, flatulence, and stool consistency on 
a  daily  and/or  weekly  basis  one  week  prior  to  the  beginning  of  the  study,  during the four-week 
treatment period, and in the two-week follow-up period. At the end of the treatment and follow-up 
periods, participants also completed on-line “quality of life questionnaires”.  
Upon a request by EFSA for clarification on the validation of the questionnaires used in the study to 
assess changes in gastro-intestinal symptoms during an intervention, and particularly in relation to 
their on-line use, the applicant referred to a consensus opinion and guidelines on the design of trials 
for functional gastro-intestinal disorders, and to a series of clinical trials on the efficacy of Tegaserod, 
a partial serotonin agonist, in treating symptoms of irritable bowel syndrome. However, the Panel 
considers that the evidence provided by the applicant did not establish that the on-line questionnaires 
used  in  the  study  to  assess  individual  gastro-intestinal  symptoms  (abdominal  pain,  abdominal 
bloating, flatulence and “bowel movements”) have been validated to be integrated into an overall 
measure  of  functional  gastro-intestinal  discomfort.  The  Panel  also  notes  that  subjective  global Bimuno
® GOS and reducing gastro-intestinal discomfort 
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assessment  of  symptoms  used  to  characterise  the  study  population  (flatulence,  abdominal  pain, 
abdominal bloating and bowel movement urgency) at baseline has been recommended as the primary 
outcome of efficacy (on which the main results should be based) for trials investigating functional 
gastro-intestinal disorders in the consensus opinion provided by the applicant and others published 
thereafter. 
The Panel notes that the effect of Bimuno
® GOS on the subjective global assessment of symptoms, a 
combined measure of efficacy which would indicate whether the intervention provided adequate relief 
of  symptoms  of  gastro-intestinal  discomfort,  was  not  assessed,  and  that  measures  of  individual 
gastro-intestinal symptoms through validated questionnaires may only be used as supportive evidence 
for the scientific substantiation of health claims on the reduction of gastro-intestinal discomfort. In 
addition, the Panel notes the reported effects of Bimuno
® GOS on three out of the five individual 
outcomes investigated (i.e. abdominal pain, bloating and flatulence, but not in “bowel movements” or 
stool consistency) did not translate into a significant improvement of the subjects’ quality of life, 
which  reveals  inconsistency  in  the  results.  The  Panel  considers  that  this  study  does  not  provide 
information about the effect of Bimuno
® GOS on relieving subjects from gastro-intestinal discomfort. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of Bimuno
® GOS and reducing gastro-intestinal discomfort. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of  health claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular,  Article 13(5) of this  
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to chi ldren’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 16/01/2014. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed  scientific  evidence.  The  application  included  a  request  for  the  protection  of 
proprietary data. 
  On 31/01/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 06/02/2014, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 13/02/2014. 
  On 10/04/2014, the NDA Panel agreed on a list of questions for the applicant to provide 
additional  information  to  accompany  the  application  and  the  clock  was  stopped  on 
14/04/2014 in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
  On 23/04/2014, EFSA received the requested information and the clock was restarted. 
  On 07/05/2014, the Working Group Claims of the NDA Panel agreed on a list of questions for 
the applicant to provide additional information to accompany the application and the clock 
was stopped on 16/05/2014. 
  On 23/05/2014, EFSA received the requested information and the clock was restarted. 
  During  its  meeting  on  25/06/2014,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Bimuno
® GOS 
and reducing gastro-intestinal discomfort.  
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to:  Bimuno
® GOS and reducing 
gastro-intestinal discomfort. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Bimuno
® GOS and reducing gastro-intestinal discomfort 
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EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of Bimuno
® GOS, a positive assessment of its safety, nor a decision on whether Bimuno
® 
GOS is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen 
in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Clasado Limited, Regent House, Office 25, Bisazza Street, Sliema, 
SLM 1641, Malta. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 for seven published studies (Tzortzis et al., 2005a, b; Goulas et al., 
2007; Depeint et al., 2008; Vulevic et al., 2008; Silk et al., 2009; Drakoularakou et al., 2010) and two 
unpublished studies (Vulevic et al., undated; Tzortzis et al., 2013) The application also includes a 
request  for  protection  of  proprietary  data  for  analytical  and  stability  data  pertaining  to  the 
manufacturing process. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituents that are the subject of the health claim are galacto-
oligosaccharides  from  Bimuno
®
  (Bimuno
®  GOS),  which  are  a  mixture  of  β-linked  galacto-
oligosaccharides (β-1→3, β-1→4, β-1→6) with a degree of polymerisation ranging between 2 and 5 
and α-linked galacto-oligosaccharides (α-1→6) with a degree of polymerisation of 2. 
Health relationship as claimed by the applicant 
According to the applicant, Bimuno
® GOS acts to reduce bloating, flatulence and abdominal pain. 
These effects can be described collectively as “abdominal discomfort”.   
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Regular daily consumption 
of 1.37 g galacto-oligosaccharides from Bimuno
® may reduce abdominal discomfort”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, 1.37 g of galacto-oligosaccharides from Bimuno
® should be consumed 
once daily for a minimum of seven days.  
The target population as proposed by the applicant is the general male and female adult population. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is Bimuno
® GOS, a mixture of β-galacto-
oligosaccharides, which is produced through conversion of lactose by enzymes from Bifidobacterium 
bifidum NCIMB 41171.  
Based on chemical analyses that were provided on five batches, Bimuno
® powder contains a mixture 
of β-galacto-oligosaccharides (Bimuno
® GOS, 47-53 %), lactose (25-35 %), glucose (6-10 %) and 
galactose (4-7 %). 
Bimuno
® GOS comprises a mixture of β-linked galacto-oligosaccharides (β-1→3, β-1→4, β-1→6) 
and  α-linked  galacto-disaccharides  (α-1→6).  The  ratio  of  β-linked  galacto-oligosaccharides  to 
α-linked galacto-disaccharides is 93:7.  Bimuno
® GOS and reducing gastro-intestinal discomfort 
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The results of stability tests showed that the Bimuno
® powder is stable for up to two years.  
The Panel considers that the food constituent, Bimuno
® GOS, which is the subject of the health claim, 
is sufficiently characterised.  
2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “reduce bloating, flatulence and abdominal pain: 
these effects can be described collectively as abdominal discomfort”. The target population proposed 
by the applicant is the general adult population.  
Symptoms such as abdominal pain, cramp, bloating, straining, borborygmi (rumbling) and sensation 
of incomplete evacuation are associated with gastro-intestinal discomfort. Reducing gastro-intestinal 
discomfort  is  considered  an  indicator  of  improved  gastro-intestinal  function.  Gastro-intestinal 
discomfort may be measured by using validated subjective global symptom severity questionnaires 
(such as described in the consensus opinions by Veldhuyzen van Zanten (1999) and Irvine et al., 
(2006)). 
The Panel considers that reducing gastro-intestinal discomfort is a beneficial physiological effect.  
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed with the following key words: abdominal pain 
prebiotic,  bloating  prebiotic,  flatulence  prebiotic,  IBS  prebiotic,  galactooligosaccharide  bloating, 
galactooligosaccharide digestion, galactooligosaccharide gastrointestinal, bloating colonic microbiota, 
galacto  oligosaccharide,  trans  galactooligosaccharide,  transgalactooligosaccharide,  transgalacto 
oligosaccharide. No restrictions related to publication dates, types or languages were applied by the 
applicant.  
The applicant identified four human intervention studies (Depeint et al., 2008; Vulevic et al., 2008; 
Silk et al., 2009; Drakoularakou et al., 2010) and one review publication (Tzortzis, 2009) as being 
pertinent to the health claim. The applicant also provided two unpublished human intervention studies 
(Vulevic et al., undated; Tzortzis et al., 2013) and three non-human studies (Tzortzis et al., 2005a; 
Searle et al., 2009, 2010) for the scientific substantiation of the claim. 
Except for the unpublished human intervention study by Tzortzis et al. (2013), all the human and 
non-human  studies  provided  by  the  applicant  for  this  claim  were  already  submitted  in  previous 
applications for the same claim, and which were assessed by the Panel with unfavourable outcomes 
(EFSA NDA Panel, 2011, 2013). 
The  multicentre  (UK,  France,  Germany,  Spain),  placebo-controlled,  randomised,  double-blind, 
parallel  study  by  Tzortzis  et  al.  (unpublished, 2013) investigated the effect of Bimuno
®  GOS on 
symptoms  related  to  gastro-intestinal  discomfort  in  subjects  (aged  18-65  years)  suffering  from 
gastro-intestinal discomfort (bloating, flatulence, abdominal pain and/or need to defecate) in the past 
12 months.  Participants  were  selected  based  on  a  composite  score  of  abdominal  symptoms  (i.e. 
flatulence, “bowel moments”, abdominal pain and abdominal bloating). Subjects were excluded if 
they had organic disease of the gastro-intestinal tract or malignancy in the past five years, were under 
medication for “gastro-intestinal conditions” or had consumed “probiotic” or “prebiotic” preparations 
at least three times per week in the previous two weeks. 
Participants completed on-line questionnaires on their “bowel habits” on a daily and weekly basis one 
week  prior  to  the  beginning  of  the  study,  during  the  four-week  treatment  period  and  during  the 
two-week  follow-up  period.  At  the  end  of  the  treatment  and  follow-up  periods,  participants  also 
completed on-line “quality of life questionnaires”. Upon a request by EFSA for clarification on the Bimuno
® GOS and reducing gastro-intestinal discomfort 
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questionnaires used, the applicant provided the forms that were completed on a daily and weekly basis 
to  collect  information  on  “bowel  movements”,  abdominal  pain,  bloating,  flatulence,  and  stool 
consistency (recorded only in the daily questionnaire). Different scales were used in the daily and 
weekly  questionnaires  to  describe  abdominal  symptoms.  In  the  daily  questionnaires,  number  of 
“bowel movements” was recorded; a scale from “0 = none” to “6 = preventing normal daily activity” 
was used for abdominal pain, bloating, flatulence; a scale from “1 = hard” to “4 = watery” was used 
for stool consistency. In the weekly questionnaire, a generic indication that “0 means none” and “6 
means a lot” was used to describe the difficulty experienced in relation to bowel movements, and 
flatulence, whereas a generic indication that “0 means not at all” and “6 means very” was used to 
describe the severity of symptoms for abdominal pain, and bloating. Another scale from “0 = none” to 
“3 = severe” was used to describe symptoms related to several factors including flatulence. The on-
line forms used for the “quality of life questionnaires” were also provided. 
Subjects who met the inclusion and exclusion criteria and had a weekly average composite score of 
> 10 to questions on flatulence, “bowel moments” (difficulty, urgency, straining, sense of incomplete 
evacuation),  abdominal  pain  and  abdominal  bloating  in  the  week  prior  to  randomisation  were 
randomised to consume Bimuno
® GOS (1.37 g/day; n = 208) or maltodextrin (n = 200) daily for four 
weeks. At the beginning of the trial, participants were asked to choose the formulation of the study 
products they intended to consume, i.e.  powder (2.75 g/sachet) or syrup (5.7 g/sachet). The study 
products were supplied to participants in white sachets (30 sachets/box) by post together with the 
instructions  for  use.  During  the  trial,  the  use  of  antibiotics  and  other  “colonic  functional  food 
ingredients (i.e. probiotics, prebiotics and synbiotics)” was not allowed, whereas all other medications 
were allowed but not monitored. The Panel notes that this study was not controlled for the use of 
medications  (e.g.  antispasmodics,  pain  killers,  antidepressants)  which  may  have  affected  the 
gastro-intestinal symptoms assessed or their perception by the subjects. Treatment compliance was 
monitored through the daily completion of the on-line questionnaires and weekly communication with 
participants. Upon a request by EFSA for clarification, no data on compliance with the study products 
for the intervention and the control groups were provided by the applicant.  
In the study report, baseline characteristics of the study subjects in relation to age, gender, weight, 
body mass index, and “irritable bowel syndrome (IBS) medication” were provided. Upon a request by 
EFSA  for  clarification,  the  applicant  also  provided  baseline  characteristics  in  relation  to  “bowel 
movements”,  stool  consistency,  abdominal  pain,  bloating  and  flatulence,  and  clarified  that  “IBS 
medication” meant any medication used for the treatment or relief of gastro-intestinal discomfort.   
In the study report, the applicant stated that the subjective global assessment (SGA) of symptoms 
(flatulence, abdominal pain, abdominal bloating, bowel movement urgency), which was assessed at 
weekly intervals and scored from 0 to 6 (0 = none; 6 = a lot), and the weekly average of abdominal 
pain, abdominal bloating, flatulence and “bowel movements” were the primary measures of efficacy. 
The Panel notes that a validated, combined SGA of symptoms (flatulence, abdominal pain, abdominal 
bloating,  bowel  movement  urgency)  may  be  an  appropriate  outcome  measure  of  gastro-intestinal 
discomfort.  However,  the  results  of  the  SGA  were  not  provided.  Upon  a  request  by  EFSA  for 
clarification on the primary outcome which was used for power calculations, the applicant indicated 
that  the  primary  endpoints  used  to  power  the  study  were  abdominal  pain,  abdominal  bloating, 
flatulence and “bowel movements”, and that for such calculations data from the study by Vulevic et 
al. (unpublished) were used. The applicant also indicated that the results of the SGA of symptoms 
(combined) with details of analysis were available in the analysis report which combined daily and 
weekly responder analyses. However, the Panel notes that the analyses combining the results from 
daily and weekly questionnaires were provided only for the individual symptoms (abdominal pain, 
abdominal bloating, flatulence and “bowel movements”) and not for the combined SGA of symptoms. 
Upon a request by EFSA for clarification on the validation of the questionnaires used in the study to 
assess changes in gastro-intestinal symptoms during an intervention, and particularly in relation to 
their on-line use, the applicant referred to a consensus opinion (Veldhuyzen van Zanten et al., 1999) Bimuno
® GOS and reducing gastro-intestinal discomfort 
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and guidelines on the design of trials for functional gastro-intestinal disorders, and to a series of 
clinical trials on the efficacy of Tegaserod, a partial serotonin agonist, in treating IBS symptoms, the 
results of which are summarised in a Cochrane systematic review and meta-analysis (Evans et al., 
2007).  The  Panel  notes  that  an  assessment  which  integrates  the  symptoms  associated  with 
gastro-intestinal discomfort (SGA) used to characterise the study population (flatulence, abdominal 
pain, abdominal bloating, and bowel movement urgency in the case of Tzortzis et al., unpublished, 
2013) has been recommended as the primary outcome of efficacy (on which the main results should 
be  based)  for  trials  investigating  functional  gastro-intestinal  disorders  in  the  consensus  opinion 
provided by the applicant and others published thereafter (Veldhuyzen van Zanten et al., 1999; Irvine 
et al., 2006). The Panel also notes that the clinical studies quoted by the applicant on the efficacy of 
Tegaserod in treating IBS symptoms adhere to that recommendation. The applicant argued that the 
questionnaires used in the study by Tzortzis et al. (unpublished, 2013) were similar. The applicant 
also stated that “the questionnaires, in all four languages used, which are Likert scale-based, were 
validated for comprehension and accuracy during the screening period against their printed version”. 
However, the Panel considers that the evidence provided by the applicant did not establish that the 
on-line questionnaires used in the study by Tzortzis et al. (unpublished, 2013) to assess individual 
gastro-intestinal symptoms (abdominal pain, abdominal bloating, flatulence and “bowel movements”) 
have been validated to be integrated into an overall measure of functional gastro-intestinal discomfort.  
A total of 34 subjects (n = 7 in the intervention group; n = 27 in the control group) discontinued the 
study for different reasons (e.g. not answering calls, not willing to continue for unspecified reasons). 
One subject in the control group experienced an adverse event (increased abdominal pain) which, 
after medical examination, was considered to be unrelated to the trial. Upon a request by EFSA for 
clarification, the applicant indicated that the “per protocol (PP)” population was calculated as the 
number of completers who filled in the questionnaires for at least four days during each week of the 
study. The Panel notes that the applicant’s definition of “PP” population, calculated as the number of 
completers,  did  not  take  into  account  subjects’  compliance  with  the  study  products,  and  that 
compliance data were not provided by the applicant. The applicant provided data on gastro-intestinal 
symptoms at baseline and at the end of the treatment and follow-up periods for the population of 
completers (n = 373 subjects, n = 172 in the control and n = 201 in the intervention groups).  
For each individual outcome (“bowel movement”, stool consistency, abdominal pain, bloating, and 
flatulence),  but  not  for  the  SGA  of  symptoms,  the  means  of  weekly  averages  from  the  daily 
questionnaires and the scores from weekly questionnaires were calculated and analysed with a linear 
mixed model. Daily and weekly scores were analysed separately and combined. Responders’ analyses 
for each outcome were also performed using logistic regression. Each participant was identified as 
being a “responder” for each endpoint if there was at least a 30 % decrease in their average response 
for  at  least  two  weeks  on  treatment  compared  to  the  average  screening  response  (daily 
questionnaires),  in  their  weekly  response  for  at  least  two  weeks  on  treatment  compared  to  the 
screening response (weekly questionnaires), and if they had at least a 30 % reduction from screening 
in their daily responses averaged over each week and at least a two-category decrease in their weekly 
score compared to screening, in the same week, for at least two weeks during the treatment period 
(combined analyses). The Panel notes that subjects with scores 0 or 1 at baseline for a given outcome 
were excluded from the responders’ analyses instead of considering them as non-responders. The 
Panel also notes that the last observation carried forward (LOCF) was used to input missing values for 
daily scores (up to six per week in the intention-to-treat (ITT) population, up to three per week in the 
population of “completers”). 
The  Panel  notes  that  the  effect  of  Bimuno
®  GOS  on  the  subjective  global  assessment  (SGA)  of 
symptoms, a combined measure of efficacy which would indicate whether the intervention provided 
adequate relief of symptoms of gastro-intestinal discomfort, was not assessed, and that measures of 
individual  gastro-intestinal  symptoms  through  validated  questionnaires  may  be  used  only  as 
supportive  evidence  for  the  scientific  substantiation  of  health  claims  on  the  reduction  of 
gastro-intestinal discomfort. In addition, the Panel notes the reported effects of Bimuno
® GOS on Bimuno
® GOS and reducing gastro-intestinal discomfort 
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three out of the five individual outcomes investigated (i.e. abdominal pain, bloating and flatulence, 
but not in “bowel movements” or stool consistency) did not translate into a significant improvement 
of the subjects’ quality of life, which reveals inconsistency in the results.  
The Panel also notes the methodological limitations of this study (i.e. lack of evidence that the on-line 
questionnaires have been validated in relation to the use of individual gastro-intestinal symptoms as 
primary measures of efficacy; lack of control for the use of medications such as antispasmodics, 
painkillers or antidepressants which may have affected the gastro-intestinal symptoms assessed or 
their perception by the subjects; the use of a single imputation method for the handling of missing 
values;  the  exclusion  of  subjects  with  scores  0  or  1  at  baseline  for  a  given  outcome  from  the 
responders’ analyses). The Panel considers that this study does not provide information about the 
effect of Bimuno
® GOS on relieving subjects from gastro-intestinal discomfort. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of Bimuno
® GOS and reducing gastro-intestinal discomfort. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food constituent, Bimuno
® GOS, which is the subject of the health claim, is sufficiently 
characterised. 
  The claimed effect proposed by the applicant is “reduce bloating, flatulence and abdominal 
pain  these  effects  can  be  described  collectively  as  abdominal  discomfort”.  The  target 
population  proposed  by  the  applicant  is  the  general  adult  population.  Reducing 
gastro-intestinal discomfort is a beneficial physiological effect.  
  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of 
Bimuno
® GOS and reducing gastro-intestinal discomfort. 
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